Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Free Dating
Ñompany Maksim-LLC. Ýëåêòðîïðèâîäû. Made and sell.
Popular Articles

One-year Phase III Study Confirms Ilaris(R) Offers Long-term Remission In Patients With CAPS, A Severe Lifelong Auto-inflammatory Disease
New results from a one-year Phase III study have confirmed that the investigational biological therapy Ilaris® (canakinumab, formerly ACZ885)[1] produced rapid and sustained remission of symptoms in the majority of children and adults with a rare and potentially life-threatening auto-inflammatory disease called cryopyrin-associated periodic syndrome (CAPS)1,2,3.
new payday loan lenders
Oral Piercings Pose Potential Health Care Risks
Like clothing and hairstyles, oral piercings give teens and adults a way to express themselves. While trendy, this fashion statement poses a number of potential oral and overall health care risks. It"s also important to note that oral piercings most commonly involve the tongue, and also the lips, cheeks, uvula or a combination of sites. Oral piercings have been implicated in a number of adverse oral and systemic conditions.
News of the day
Brain Activity Stablilized By Dynamic Molecular Mechanism
In the brain, many types of synaptic proteins are spatio-temporally regulated to maintain synaptic activity at a constant level. Here, the Japanese research group led by Professor Masaki Fukata, Drs. Yuko Fukata and Jun Noritake in National Institute for Physiological Sciences, Japan, found that two types of palmitoylating enzymes finely-tune the location and function of a major synaptic protein, PSD-95, in different ways. They also found that this mechanism contributes to keeping synaptic activity stable when synaptic activity dynamically changes. The Japan Science and Technology Agency (JST) supported this study. They report the finding in Journal of Cell Biology published on July 13, 2009.
Endocrinology

NICE Welcomes Office For Life Sciences New Blueprint To Support Innovative Drugs

NICE today welcomed the Office for Life Sciences new Blueprint to support the life sciences industry, which will also improve patient access to innovative new drugs. Welcoming the Blueprint launch, Andrew Dillon Chief Executive of NICE said: "Securing a successful future for the life sciences industries is important for patients and the UK economy.The Innovation Pass is an opportunity for data to be gathered on potentially important new treatments. NICE has been involved in discussions about the Innovation Pass, and we are looking forward to continuing to play a key role in developing the pass." Mr Dillon continued: "NICE is committed to engaging constructively with the pharmaceutical industry and we are extending the access that companies have to us, as we appraise their products. Later this year, we will begin asking pharmaceutical and other life sciences companies, whose products we are evaluating, to make technical staff available to engage with our advisory Appraisal Committees. They will be able to respond to requests from committee chairs to clarify the data they have submitted and to point out any error of fact in the presentation of their data. We believe that this will give companies more confidence in the way NICE handles the evaluation of their products." NICE


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009